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Radioimmunotherapy (RIT†) of lymphoma with Zevalin and Bexxar was approved by FDA
in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular
B-cell non-Hodgkinﾴs lymphoma. In 2009, Zevalin was also approved for consolidation ther-
apy in patients with follicular non-Hodgkin’s lymphoma that achieve a partial or complete re-
sponse to first-line chemotherapy. For follicular lymphoma patients, the overall response
and progression-free survival rates have significantly improved since the implementation of
RIT. The predominant complication of RIT is hematological toxicity that is usually manage-
able. There are ongoing trials to further define the expanding role of RIT as first line or con-
comitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant
infections and aggressive malignancies. There is also growing interest in the development
of newer protocols for increased and more uniform dose delivery resulting in better out-
comes and improved patient survival. This review will primarily focus on the role of RIT in
treatment of non-Hodgkin’s lymphoma, which is of established clinical utility and FDA ap-
proved. The mechanism of RIT, available radionuclides and pharmacokinetics, therapy ad-
ministration, clinical utility and toxicities, and future directions would be discussed.  
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of Nuclear Medicine, 211 East Gun Hill Road, Montefiore Medical Center, Bronx, NY
10461; E-mail: rmoadel@montefiore.org.
†Abbreviations: NHL, Non-Hodgkin’s Lymphoma; HD, Hodgkin’s Lymphoma; RIT, ra-
dioimmunotherapy; mAb, monoclonal antibody; HAMA, human anti-mouse antibody;
HACA, human anti-chimeric antibody; ORR, overall objective response rate; CR, com-
plete response; PR, partial response; PFS, progression-free survival; TP, time to progres-
sion; DR, duration of response; MDS, Myelodysplastic syndrome; AML, acute myeloid
leukemia; RBE, relative biological effectiveness; LET, linear energy transfer.
Keywords: lymphoma, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, radioimmunother-
apy, immunotherapy, Bexxar, Zevalin, Dosimetry, Y-90, Rituximab, monoclonal antibody,
beta particle, alpha particle, Auger, biodistributionINTRODUCTION
Immunotherapy  utilizes  the  antibody-
antigen mechanism to enhance or suppress the
immune response for management of various
disorders. Different immunomodulators that
selectively modify the immune response have
been used clinically with significant success,
such  as  Rituximab  (Rituxan,  lymphoma),
Trastuzumab (Herceptin, breast cancer), Alem-
tuzumab (Campath-1H, chronic lymphocytic
leukemia),  Cetuximab  (Erbitux,  colorectal
cancer), and Bevacizumab (Avastin, colorectal
and lung cancers).
Radioimmunotherapy (RIT) uses mon-
oclonal antibodies (mAb) directed against
specific tumor antigens labeled with a parti-
cle emitting radioisotope to deliver radiation
directly to the tumor. Radio immunotherapy
combines the synergistic effects of both ra-
diation and immunotherapy with manage-
able local and systemic side effects. The
characteristic and complex interactions be-
tween the tumor, host, radionuclide, and the
antigen-antibody complex determine the ef-
fectiveness of RIT. RIT has an established
role in treatment of lymphoreticular malig-
nancies [1], but it has not proven effective
for the treatment of solid tumors due to lim-
itations with antibody penetration within the
central portions of larger tumors.  However,
RIT has a promising role in the treatment of
bone metastases, prostate cancer, metastatic
melanoma, ovarian, leukemia, high-grade
brain tumors, metastatic colorectal cancer,
neoplastic meningitis, and resistant fungal
and viral infections through binding of ra-
dionuclides to antibodies, thereby targeting
the corresponding antigens. An ideal radio-
immunotherapeutic scenario offers selective
targeting of a radiosensitive tumor with min-
imal toxicity (unique antigen expression,
high affinity of the antigen-antibody bind-
ing, antigen that is not shed, internalized, or
modulated, uniform distribution, similar bio-
profile of the constituents, optimal tumor
residence time and penetration, improved
progression-free survival, minimal HAMA-
human anti-mouse antibody and HAHA-
human  anti-chimeric  antibody  responses,
possible repeat administration, etc.). Also,
other logistics such as availability, ease of
labeling process, stability of the radio-im-
munoconjugate, cost effectiveness, outpa-
tient  administration,  minimal  radiation
safety precautions, etc. are important con-
siderations during the design of an ideal
radio-immunoconjugate for therapy.
Radionuclides with beta decay (131I, 90Y,
177Lu, 186Re, 188Re, 67Cu), alpha decay (211At,
212Bi, 213Bi, 225Ac) and low energy electrons
(125I, 67Ga ) have the potential for use in RIT.
The general properties of various decay par-
ticles used in radiotherapy are outlined in
Table 1 [2]. The characteristics of the ra-
dionuclide strongly influence the effective-
ness and toxicity of the therapy [3]. This
clinical realm of applications is rapidly ex-
panding with a possible role in the manage-
ment of several resistant and untreatable
conditions. This review will primarily focus
on the RIT of lymphomas, which is of es-
tablished clinical utility and FDA approved.
Beta decay radionuclides have been ex-
tensively used for radionuclide treatments
and offer better radiopharmaceutical charac-
teristics for design and therapy administra-
tion. The unique characteristics of cross fire
effect, adequacy of delivery to cell surface
added to the ease of labeling, and availability
led to widespread use of beta particle ra-
dioimmunoconjugates. The improved effec-
tiveness  of  antibodies  labeled  with  beta
emitting radionuclides relates to the phenom-
enon of “cross fire” or “by-stander” effect [4],
where in the tumor cells within close range
of the targeted cell are also killed secondary
to beta ionizing radiation irrespective of the
antigen expression. The radiation safety pre-
cautions  for  beta  decay  radionuclides  are
minimal unless there is a coexisting gamma
radiation. 
Alpha decay results in denser ionizations
with  much  higher  linear  energy  transfer
(LET) and relative biological effectiveness
(RBE) and also can be employed in hypoxic
conditions. However, the range is only mi-
crons, and thus, it requires actual binding of
the therapeutic agent to the cancer cell itself
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cross fire effect with alpha decay, which is
one of the advantages of beta particles). Also,
the alpha emitting radionuclides are usually
either short-lived (that limits the duration of
their biological effectiveness) or decay to a
beta  emitting  daughter  product  with  long
half-life (for example, 207Bi is the daughter ra-
dionuclide of 211At and has a half-life of ~30
years). Alpha emitting radionuclides pose a
significant challenge for the design of RIT
compound due to short half-life and in vivo
metabolic instability. However, due to signif-
icant sparing of healthy tissues with alpha
emitting agents, there is growing interest in
the application of alpha therapy as adjunctive
treatment for patients with residual disease. 
Low energy electrons have relatively
dense ionizations with high toxicity, but they
need to be incorporated into the nucleus of
the target cell due to their extremely short
range of nanometers. The success of Auger
electron therapy depends on selective deliv-
ery and stable bio-localization of the ra-
dioimmuno conjugate into the nucleus of all
the tumor cells, and this poses a significant
challenge for radiopharmaceutical design. 
RIT OF LYMPHOMAS
Lymphomas  are  malignancies  of  the
lymphoid tissue and are broadly classified
into Hodgkin’s lymphoma (HD) and non-
Hodgkin’s lymphomas (NHL, 85 percent).
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Table 1: Therapeutic Radionuclides [2]
Emission
Energy
Range
Path track
Ionizations
Linear Energy
Transfer
Mechanism
Relative Biological
Effectiveness
Requisite
Clinical application
Cross fire effect
Radiation safety
Beta decay
Negative charged electron
0.05 – 2.5 MeV
0.2 – 15 mm
Tortuous
Less dense
0.2 keV/ʼm
Cross fire effect, half-
life and radioactivity
dependent, Oxygen
dependent
Low
Close to target/cell 
surface
FDA approved
Yes
Minimal; other 
precautions if coexisting
gamma decay
Low energy 
electron decay
Auger electrons
10 eV-10 keV
nanometers
contorted 
Relatively dense but
only in immediate
vicinity
4 – 26 keV/ʼm
Breaks in DNA
strands 
Low
Incorporation into
nucleus
Experimental
No
Minimal
Alpha decay
Helium nucleus
2-10 MeV
10-500 ʼm
Straight
Dense
80 – 300 keV/ʼm
Traversed path
length in the cell 
nuclei, Oxygen 
independent
High
Binding to cancer
cell
Experimental
No
Minimal, avoid 
inhalation/ingestionNon-Hodgkin’s lymphomas are a heteroge-
neous group of lymphoreticular malignan-
cies with a wide range of aggressiveness.
The majority of NHL are B-cell lymphomas,
with the follicular and diffuse large B-cell
lymphomas constituting up to 50 percent of
NHL. NHL can also be classified as indolent
(40 percent) or aggressive lymphomas (60
percent).  B-cell  CLL/small  lymphocytic
lymphoma, marginal zone lymphoma, lym-
phoplasmacytoid and follicle center lym-
phoma  constitute  the  indolent  types,
whereas diffuse large B-cell, mantle cell,
Burkitt’s and precursor B-cell leukemia con-
stitute the aggressive types. NHL accounts
for 4 percent of all malignancies and 4 per-
cent of all cancer relate deaths [5]. The TNM
staging cannot be applied for lymphomas
and a pathological WHO/REAL classifica-
tion [6] integrating the cytological, molecu-
lar, and immunological information is in
current use. The Ann Arbor staging is used
for clinical staging of both HD and NHL [7].
Various prognostic scores and classifications
have been developed to risk stratify the pa-
tients [8]. The initial staging and histological
grade are important factors that determine
the patient’s prognosis. 
Pressman et al. [9] reported the initial
localization of 131I polyclonal antibodies to
tumor cells in rabbits, and Bierwaltes et al.
[10] reported their therapeutic potential in
human metastatic melanoma. Subsequently,
monoclonal antibody technology (mAb) was
developed by Kohler and Milstein in 1975
[11], thereby opening doors for selective tar-
geting. DeNardo et al. [12] first described
the successful use of RIT with Lym-1 (131I
labeled  anti  B-cell  lymphoma  mAb)  in
NHL. The use of anti CD-20+ mAbs was
described by Nadler et al. [13], and subse-
quently, the use of 131I and 90Y anti CD-20+
mAbs was described [14]. Since then, sev-
eral modifications and new protocols were
reported.
More than 90 percent of the lymphoma
B-cells demonstrate cell surface CD-20+
antigen (a human B-lymphocyte restricted
differentiation antigen), which is expressed
only on mature B-cell lineage and not found
on stem or plasma cells. The CD-20+ anti-
gen serves the function of cell cycle initia-
tion and differentiation and is not shed, in-
ternalized,  or  modulated  [15,16,17].
Rituximab (Rituxan) is a chimeric (murine
and human) monoclonal antibody targeting
CD-20+ antigen on both malignant and nor-
mal mature B-cells. Binding of Rituximab
with CD-20+ antigen triggers various cellu-
lar pathways that result in apoptosis, anti-
body  dependent  cytotoxicity,  and
complement  dependent  toxicity  with  an
overall improvement in treatment response
rates [18]. 
ZEVALIN AND BEXXAR
The two currently FDA-approved thera-
peutic agents for management of lymphoma
are 90Y ibritumomab tiuxetan (Zevalin, Cell
Therapeutics Inc, Seattle, WA, and Schering
AG, Berlin, Germany; 2002) and 131I tositu-
momab (Bexxar, GlaxoSmithKline, Research
Triangle Parks, NC; 2003). The indications and
contraindications for RIT in the treatment of
lymphoma are detailed below. The properties
of Zevalin and Bexxar are compared in Table 2.
Radio-immunoconjugates
Zevalin  is  90yttrium  labeled  ibritu-
momab tiuxetan. 90Y (90yttrium) is produced
from decay of Strontium-90. 90Y is a pure
beta emitter that decays to non-radioactive
stable Zirconium-90 with a half-life of 64 h
(2.7 d). The max energy of the beta emission
is 2.29 MeV, and it has an effective path
length of 5.3 mm (meaning 90 percent of its
energy is absorbed within a sphere with a 5.3
mm radius or about 100-200 cell diameters).
The beta emission from 90Y has a longer path
length than that of  131I, which is advanta-
geous in tumors with heterogeneous anti-
body distribution as it permits radiation to a
larger area. Ibritumomab is a murine IgG-1
kappa anti-CD20+ antibody genetically en-
gineered  from  a  Chinese  hamster  ovary
(CHO) line that is conjugated to Y90 in the
presence of a chelate tiuxetan (Mx-DTPA).
The median biological half-life of Zevalin in
blood is 48 hours with clearance primarily
through the genitourinary system. Approxi-
mately, 7 percent of the administered dose is
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Table 2: Comparison of Zevalin and Bexxar
Components
Antibody
Ease of Labeling
Availability
Radionuclide
Max beta energy (mean)
Principal gamma 
emissions
Effective mean path
length
Half life
Clearance
Critical organ
Cold antibody
Diagnostic scan purpose
Dose determination
Pre-therapy preparation
Hematological toxicity
Other unique toxicities
HAMA
Myelodysplastic syndromes
(MDS/AML)
Radiation precautions
Therapy setting
Zevalin
90Y ibritumomab tiuxetan
Murine IgG-1 kappa antibody
to CD20+
More complex
Available in uS, Canada,
and Europe
90Y
2.29 MeV (0.9 MeV)
None
5.3 mm
2.7 d
urinary
Spleen, testes
Rituximab
Bio-distribution
Fixed based on weight and
platelets (0.4 or 0.3 mCi/kg)
Antihistamines/NSAID
Predominant toxicity
Dehalogenation in liver, and
effect on marrow
2%
1.4 – 5.2%
universal for 1 week
Outpatient
Bexxar
131I tositumomab
Murine IgG2a lambda antibody
to CD20+
Ease
Not available in Europe
131I
0.6 MeV (0.19 MeV)
364 keV
0.8 mm
8.04 d
urinary, faster
Thyroid
Tositumomab
Dosimetry and bio-distribution
Clearance rate/dosimetry
based to deliver 75cGy or
65cGy total body dose
Additional thyroid blocking 
Predominant toxicity, less
severe than Zevalin
Hypothyroidism
20% or more
10%
Additional precautions for
gamma radiation
Majority outpatienteliminated through urine within the first 7
days. The estimated tumor absorbed radia-
tion dose is 15 Gy (1500 rad), with a tumor-
to-normal organ ratio of 7:1. 
Bexxar is 131I covalently linked to tositu-
momab, a murine IgG2a lambda monoclonal
antibody also directed to CD-20+ antigen. 131I
is a beta and gamma emitter with a physical
half-life of 193 h (8.04 days). The max beta
energy is 606 keV (mean 191.6 keV), and the
principal gamma emission has energy of 364.5
keV (82 percent). The mean path length is 0.4
to 0.8 mm. The median total body effective
half-life for Bexxar is 67 hours (28-115 hours),
and elimination occurs predominantly through
urine (67 percent is cleared within 5 days).
Indications and Contraindications
Zevalin therapy is indicated for relapsed
or refractory, low grade or follicular B-cell
NHL lymphoma. It was approved in 2009 for
previously untreated follicular NHL patients
who achieve a partial or complete response to
first-line chemotherapy. Bexxar therapy is in-
dicated for treatment of patients with CD20+
antigen-expressing  relapsed  or  refractory,
low-grade, follicular, or transformed NHL, in-
cluding  patients  with  rituximab  refractory
NHL.
Both Zevalin and Bexxar are contraindi-
cated in the following conditions: pregnancy
or ongoing breast feeding, known allergy or
hypersensitivity to the murine antibodies, or
components of the therapy; absolute Neu-
trophil  Count  <1500  cells/cu  mm,  platelet
count <100,000; bone marrow involvement of
more than 25 percent involvement; effective
beam radiation therapy of >25 percent of ac-
tive marrow; prior autologous stem cell trans-
plant; and elevated HAMA titers with altered
biodistribution. Additional contraindications
for Bexxar therapy include iodine allergy, uri-
nary incontinence (relative contraindication),
non-compliant patients, and a reduced renal
function with creatinine > 1.5.
Treatment Administration 
Once the patient is referred for RIT
therapy, a determination needs to be made if
patient is eligible for treatment.
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Table 3a: Zevalin therapy administration protocol [19]
Step A: Patient Selection and Eligibility
Step B: Bio-distribution/ Diagnostic scan
Day 1:
Acetaminophen 650 mg and diphenhydramine 50 mg, 30 minutes prior to infusion
unlabeled rituximab infusion (250 mg/m2) at a rate of at a rate of 50mg/hr, incremental to
400mg/hr
5 mCi or 185 MBq/1.6 mg antibody (10 mL) of 111In-Zevalin slow intravenous injection over
10 minutes; administered within 4 hours of the cold antibody infusion
Days 2-6:
Whole body planar images obtained at 48-72 hours (subsequent scanning optional)
Previously, images at 2-24, 48-72, and 90-120 hours
Step C: Dose Calculation
Assess the bio-distribution and if acceptable, determine the dose (0.4 or 0.3 mCi/kg based
on platelet counts)
Step D: Therapeutic Dose Administration
Day 7/8/9: (exact timing depends on dose arrival and logistics)
Acetaminophen 650 mg and diphenhydramine 50 mg, 30 minutes prior to infusion
unlabeled rituximab infusion (250 mg/m2) at a rate of at a rate of 50mg/hr 
Calculated dose of Zevalin slow IV infusion over 10 minutes through a low protein binding
millipore filter (maximum dose 32 mCi or 1184 MBq); administered within 4 hours of the
cold antibody infusion
Flush the catheter post infusion to administer complete dose
Assay the administration tubing set For Zevalin therapy, a bio-distribution
scan is obtained as an outpatient for exclu-
sion of abnormal antibody tracer distribution
(0.6 to 1.3 percent of patients) that would
preclude treatment. Given that 90Y is a pure
beta emitter and has no gamma decay, In-
dium-111 (111In) is used a surrogate. During
the bio-distribution or pre therapy planning
stage, 111In-Zevalin is injected intravenously,
and whole body planar images are obtained
at 48 hours following administration of the
agent. Prior to dosing, patients receive a
dose of unlabeled rituximab to block CD-
20+ binding sites on B-cells in the circula-
tion and in the spleen. Upon confirmation of
the normal expected bio-distribution, a dose
of Zevalin is calculated based on patient’s
weight and platelet count. The dose of Ze-
valin is 0.4 mCi/kg (14.8 MBq/kg) in pa-
tients  with  platelet  counts  greater  than
150,000. If the platelet counts are between
100 and 150,000, the dose is decreased to
0.3 mCi/kg (11.1 MBq/kg). If platelets are
fewer than 100,000, therapy is contraindi-
cated. The maximum administered activity
of Zevalin is 32 mCi. Zevalin does not have
any gamma emissions, and the activity is
measured indirectly through Bremsstrahlung
radiation. The standardization and calibra-
tions factors are set up at the time of the ini-
tial  site  inspection.  Table  3a  details  the
protocol for administration of Zevalin ther-
apy [19].
For Bexxar therapy, the therapeutic dose
is  calculated  from  pre-therapy  dosimetric
studies after administration of a small dose
(5mCi) of 131I-tositumomab. Similar to the
Zevalin protocol, prior to tracer administra-
tion, the patient is given an infusion of unla-
beled tositumomab to bind non-tumor B-cells
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Table 3b: Bexxar therapy administration protocol [20]
Step A: Patient Selection and Eligibility
Step B: Thyroid protection
Day -1:
Saturated solution of potassium iodide (SSKI )- 4 drops orally 3 times/day or Lugol's solu-
tion 20 drops orally 3 times/day or KI tablets 130 mg orally once/day; Administered from
the day before until 14 days following therapy 
Step C: Diagnostic and Dosimetry Scan
Day 0:
Acetaminophen 650 mg and diphenhydramine 50 mg, 30 minutes prior to infusion
unlabeled tositumomab 450 mg intravenously in 50 ml saline over 1 hour
Small dosimetric amount of 131I-tositumomab (5 mCi or 185 MBq of 131I and 35 mg Tositu-
momab) in 30 ml saline over 20 minutes
Whole body dosimetry and bio-distribution immediately following injection within one hour,
pre-void
Day 2, 3 or 4:
Whole body dosimetry and bio-distribution, post void
Day 6 or 7:
Whole body dosimetry and bio-distribution, post void (to maintain consistency, the same
camera, collimator, and set up are utilized on all the dosimetric scans)
Step D: Dose Calculation
Assess the bio-distribution and if acceptable, determine the dose 
Calculate the dose to deliver 75cGy total body dose (65 cGy, if platelets are 100-150,000)
Step E: Therapeutic Dose Administration 
Day 7 up to 14: (exact timing depends on dose arrival and logistics):
Acetaminophen 650 mg and diphenhydramine 50 mg, 30 minutes prior to infusion
450 mg infusion of unlabeled Tositumomab in 50 mL of saline over 1 hour
20 minute infusion of Bexxar in a volume of 30 mL given through a millipore micron filter 
Flush the catheter post infusion to administer complete dose
Assay the administration tubing setin the circulation and spleen. Additionally,
SSKI is administered to block thyroid uptake
of 131I. Initial studies reported at least a four-
fold normal variation in the clearance of the
administered activity depending on tumor
burden, presence of splenomegaly, and extent
of bone marrow involvement. The tolerated
maximum  whole  body  radiation  dose  for
Bexxar therapy is 75cGy or 75 rad (65cGy or
65 rad, if platelets are 100,000-150,000). The
geometric whole body counts are plotted on a
semi log paper, and a residence time is calcu-
lated (time to reach 0.37 from the initial ac-
tivity, 8-24 days). The expected activity hours
from the provided data are compared to the
residence time derived from semi log graph,
and  the  resulting  activity  is  adjusted  for
platelet count to calculate the administered
activity. Refer to Table 3b for Bexxar admin-
istration protocol [20]. 
Scintigraphic Imaging and Findings
The variations in the bio-distribution of
the antibody scan images provide clues to their
recognition. The whole body antibody scan
image reflects a blood pool scan. A fragment
antibody scan results in rather intense renal ac-
tivity due to faster clearance.  111In images
demonstrate better image resolution (Figures
1 and 2) compared to 131I-Bexxar images. Pre-
loading is performed with a unlabeled anti-
body infusion for both bio-distribution and
treatment studies, in an effort to minimize the
antigen sinking effect, wherein the adminis-
tered activity predominantly targets and accu-
mulates within the normal reticuloendothelial
system and circulating lymphocytes [21]. If a
scan is performed without administration of a
pre-dosing unlabeled antibody, this would re-
sult in intense spleen and marrow uptake.
On  a  normal  pre-therapy  111In-Zevalin
scan, there is good uptake in the blood pool
areas that decreases over time, moderately high
to high uptake in the normal liver and spleen,
and moderately low to low uptake in the lungs,
kidneys, and urinary bladder. Tumor uptake
may be visualized but is not required. Altered
bio-distribution is suggested when blood-pool
activity is not visualized, lung uptake exceeds
liver activity, renal activity exceeds hepatic ac-
tivity on posterior images, and if there is more
uptake in the bowel than the liver. Increased
bone marrow accumulation of the tracer can be
seen in patients with HAMA response, tumor
involving marrow, or related to use of marrow
stimulating factors. Figure 1 demonstrates a di-
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Figure 1. 111In-Zevalin Biodistribu-
tion Scan. Anterior (a) and posterior
(b) planar images obtained at 48
hours after administration of 5mCi or
185 MBq of 111In-Zevalin intra-
venously. The images demonstrate
normal expected biodistribution
within the heart, liver, spleen and kid-
neys (yellow arrows). Also noted is
the tumoral uptake within the lymph
nodes in the abdomen, inguinal re-
gions and left lower neck and axillary
regions (red arrows). Treatment dose
would be calculated based on weight
and platelet counts. (Image courtesy:
Dr. Kent P. Friedman, MD, Depart-
ment of Radiology, NYu Radiology
Associates, NY).agnostic  111In-Zevalin obtained at 48 hours,
with normal bio-distribution and tumoral up-
take.
Normal bio-distribution of Bexxar in-
cludes blood pool activity that decreases over
time and liver and splenic activity less than
heart, which decreases over time. There may
be mild uptake within the thyroid, kidney, and
urinary bladder and minimal uptake within the
lungs. Lymphomatous tissues can demonstrate
concentration  of  the  radionuclide  with  in-
creasing activity. An abnormal bio-distribution
includes absent blood pool activity, intense
liver or spleen activity, increased lung uptake
greater than blood pool activity, findings in-
dicative of urinary obstruction, or an abnormal
calculated total body residence time (normal
50-150 hrs). Figure 2 demonstrates initial dosi-
metric Bexxar images obtained at three differ-
ent time points as per the imaging protocol.
Clinical Utility
The  CD-20+  antigen  is  densely  ex-
pressed on nearly all (more than 90 percent)
of B-cell lymphomas, and these tumors are
amenable for treatment with immunomodu-
lators. Unlabeled Rituximab treatment di-
rected  against  the  cell  surface  antigen
CD20+ has proven effective in the treatment
of B-cell non-Hodgkin’s lymphoma [22,23].
However,  lymphomas  are  generally  ra-
diosensitive tumors, and this feature offers
a unique opportunity for even more effective
treatment with radiolabeled immunomodu-
lators that are also directed against the CD-
20+ antigen. 
In a randomized pivotal trial of patients
with relapsed or refractory low-grade follic-
ular NHL, Zevalin treatment resulted in sig-
nificantly  higher  ORR  (overall  objective
response rate) and CR (complete response)
compared to unlabeled rituximab therapy
alone [24]. A multicenter randomized study
demonstrated prolonged median progression
free survival (PFS) with conversion of 77
percent of partial responders to complete re-
sponse with Zevalin for consolidation after
chemotherapeutic induction compared to a
control group [25]. These results suggest
that Zevalin may have an important role in
eliminating minimal residual disease fol-
lowing induction chemotherapy. In a pivotal
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Figure 2. 131I Bexxar Biodistribution and Dosimetric Scans. Whole body planar images
(Patient) obtained after a small dose of 131I Bexxar at day 0 (a), day 2 or 3 (b), and day 6
or 7 (c) demonstrate normal expected biodistribution. The background images (Bkgd) are
utilized to obtain the background corrected counts for purposes of dose calculation. The
standard (Std) images are obtained for quality control. Subsequent dose calculation is per-
formed based on the obtained total body counts, residence time (to account for variation in
clearance), and platelet counts (dose limiting toxicity) to deliver a therapeutic total body ef-
fective dose of 75 cGy or 75 rads. (Image courtesy: Dr. Kent P. Friedman, MD, Depart-
ment of Radiology, NYu Radiology Associates, NY).400 Chamarthy et al.: Radioimmunotherapy of non-Hodgkin’s lymphoma
Table 4: Important studies signifying the role of RIT in lymphoma
Immuno or 
radioimmuno 
conjugate
Rituximab
Rituximab + CHOP vs.
CHOP
Zevalin
Zevalin vs. 
Rituximab 
Zevalin after
chemotherapeutic in-
duction of a CR or PR
vs. control group
Bexxar vs. 
tositumomab
Bexxar vs. salvage
chemotherapy
Bexxar 
Bexxar
Bexxar after short
course of Fludarabine
Reference
McLaughlin et al., 1998
[22]
Coiffer et al., 2000 [23]
Witzig et al., 2002 [30]
Witzig et al., 2002 [24]
Morschauer et al., 2008
[25]
Davis et al., 2003 [27]
Kaminski et al., 2001
[26]
Fischer et al., 2005 [31]
Kaminski et al., 2005
[28]
Leonard et al., 2005
[29]
Results
ORR: 48%; 
CRR: 6%; 
Projected median TTP
for responders: 13m
76% vs. 63%
Higher event free and
overall survival rate, re-
duced risk of treatment
failure and death
ORR: 74%; 
CR: 15%;
Overall TTP: 6.8m
ORR: 80% vs. 56%; 
CR: 30% vs. 16%;
TTP and median DR:
no significant difference
Median PFS of 36.5m
vs. 13.3m; 
77% of PR cases con-
verted to CR with Ze-
valin
ORR: 55% vs. 19;
CR: 33% vs. 8%
ORR: 65% vs. 28%;
CR: 17% vs. 3%
ORR: 47% - 68%;
CR: 20% - 38%;
5-year PFS: 17%
ORR: 95%;
CR: 75%;
5-yr PFS: 59%
ORR: 98%;
Median PFS > 48m
Population and N
Relapsed low grade or
follicular NHL, N=166
Aggressive NHL,
N=399; randomized
study
Rituximab refractory
follicular NHL, N=54
Relapsed or refractory
follicular, low-
grade, or transformed
NHL;  N=143; 
randomized multicenter
study
Advanced stage follic-
ular lymphoma in first
remission, N=414;
multicenter random-
ized study
Relapsed or refractory
NHL, N=78; random-
ized trial 
Low grade or trans-
formed low-grade
NHL, N=60
Relapsed or refractory
low-grade, follicular, or
transformed low-grade
NHL, N=250; inte-
grated efﬁcacy analy-
sis of the previous ﬁve
clinical trials
Stage III or IV follicular
lymphoma, N=76
Early stage, N=35
ORR: Overall objective response rate; CR: Complete response; PR: Partial response; PFS: Progres-
sion free survival; TP: Time to progression; DR: Duration of response; m: monthstrial, treatment with Bexxar resulted in sig-
nificantly better ORR and CR compared to
the last chemotherapy in refractory and re-
lapsed cases [26]. Also, another randomized
trial reported significantly better overall and
complete  response  rates  with  Bexxar  as
compared to unlabeled tositumomab alone
[27]. Subsequent studies demonstrated the
utility of Bexxar alone in stage III or IV fol-
licular lymphoma and Bexxar after a short
course of Fludarabine in early stage with
better ORR and PFS rates [28,29]. Other tri-
als also reported the utility of RIT with bet-
ter ORR, CR and increased PFS, and some
of them are detailed in Table 4.
Toxicity Profile
The primary and dose-limiting side ef-
fect from RIT is hematologic toxicity.
The primary adverse effects of Zevalin
therapy are hematological toxicity with ane-
mia, thrombocytopenia and neutropenia [32].
There is a delayed nadir for the hematologi-
cal toxicity that reaches a peak at 7 to 9
weeks following treatment (which is slightly
delayed compared to standard chemother-
apy), and the duration can last 7 to 35 days.
Other side effects are flu-like symptoms, in-
cluding infection, chills, fever, abdominal
pain, and allergic reactions. Reduced renal
function and toxic skin reactions have rarely
been reported with Zevalin administration.
There is a reported small risk of developing
AML (acute myeloid leukemia) in 1.4 per-
cent of the patients between 8 and 34 months
after therapy, although myelodysplastic syn-
drome (MDS)/AML has been reported in up
to 5.2 percent of the cases. HAMA response
can develop in up to 2 percent of Zevalin
therapy patients. 
The toxicities of Bexxar are similar to
Zevalin with the predominant adverse effect
being  hematological  toxicity  resulting  in
anemia, neutropenia, and thrombocytopenia
[33]. However, these are reported to be less
severe compared to Zevalin. The median ab-
sorbed dose is highest in the thyroid (2.7
mGy or 270 mrad/MBq), and there is a risk
of hypothyroidism (6 percent) from any free
I131 following Bexxar administration. The in-
cidence of hypothyroidism increases with
the time period after therapy [34]. This em-
phasizes the significance of administering
thyroid blocking agents before and during
the therapy. HAMA response can develop in
10 percent to 50 percent of patients treated
with Bexxar (more in patients without prior
chemotherapy) and is higher compared to
Zevalin  [35].  However,  conversion  to
HAMA positivity has not been shown to be
associated with altered therapeutic efficacy.
MDS/acute leukemias were reported in up
to 10 percent of patients during a median
follow-up of 27 to 39 months, with a higher
increased  incidence  over  time  following
therapy. 
Radiation Safety
Plastic and acrylic shielding is used for
Y-90, and lead and tungsten are not appropri-
ate due to the concern for bremsstrahlung ra-
diation. Written radiation safety instructions
are not mandated, but helpful for the pa-
tients. Administration of Zevalin therapy can
be performed with minimal risk to close
contacts [32,36,37]. Universal radiation pre-
cautions should be observed post Zevalin
therapy, and emphasis should be maintained
to  prevent  contact  from  body  fluids  and
urine for up to 1 week. Usually, Bexxar can
be administered as an outpatient, and the pa-
tient can be released with appropriate pre-
cautions for I131 as per the 10 CFR 35.75
regulations that require a determination of
total effective dose equivalent to other ex-
posed individuals to be less than 5mSv (500
mrem). This determination involves a dose-
specific calculation based on individual oc-
cupancy and social factors with appropriate
written safety instructions. Previous studies
have demonstrated the feasibility of Bexxar
outpatient treatment and safe release of the
patients without exceeding the regulatory
limits to general public, family members, or
health care personnel [38]. 
DISCUSSION
The staging and treatment of lymphomas
have witnessed significant changes in the last
few decades with newer technologies (PET-
CT, tracers) and newer treatment modalities
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monoclonal antibodies. The management of
NHL includes radiation therapy, chemother-
apy, immunotherapy, combination therapy,
and stem cell transplant depending on the his-
tology, grade, and disease extent. The advan-
tage of RIT is the selective delivery of an
individualized radiation dose to the tumor
cells throughout the body with relative sparing
of  normal  tissues.  The  radiation  induced
killing of the tumor, and cross fire effect is felt
to be advantageous compared to the conven-
tional/combinational chemotherapy. Local or
extended field radiation therapy is an option;
however, its effectiveness is often limited due
to the disseminated nature of the disease, as
well as the inability to treat clinically silent
disease sites. Moreover, there is often signifi-
cant clinical toxicity from external radiation.
Both Zevalin and Bexxar are of proven clini-
cal utility and can be safely administered to
outpatients for the treatment of low-grade re-
fractory  or  relapsing  CD-20+  B-cell  lym-
phomas.  Additionally,  Zevalin  has  been
approved for consolidation therapy in previ-
ously untreated follicular NHL patients who
achieve a partial or complete response to first-
line chemotherapy. The contraindications are
similar for both the available radionuclide
treatments. 
There are no randomized clinical studies
comparing  Zevalin  and  Bexxar,  and  the
choice of radio-immunotherapeutic agent de-
pends on the tumor, institutional preferences,
and the ability of the patient to conform/im-
plement the required radiation safety precau-
tions.  RIT  can  be  only  performed  by  an
authorized user, and a written directive is
needed. Therapy administration requires safe
handling  and  radiation  safety  precautions,
with additional precautions for 131I following
Bexxar therapy. Zevalin, and most cases of
Bexxar therapy, can be performed on an out-
patient basis. In some countries other than the
United States, in-patient therapy may be pre-
ferred. Planning, treatment, and post-treat-
ment follow-up require a multidisciplinary
approach and interdepartmental coordination. 
Both Zevalin and Bexxar require an ini-
tial  diagnostic/bio-distribution  exam,  fol-
lowed by the therapeutic dose administration.
The purpose of the initial diagnostic scan for
Zevalin is to confirm a normal bio-distribu-
tion, whereas the diagnostic exam also pro-
vides  dosimetric  information  for  Bexxar
dosing. For both therapies, the predominant
toxicity is hematological with a delayed nadir
at 7-9 weeks. Serial blood counts and sup-
portive treatment is performed as needed. The
systemic side effects typically observed in as-
sociation with standard chemotherapy are not
seen with RIT. Following RIT, a slightly in-
creased risk for developing myelodysplastic
/AML disorders has been reported. An in-
creased  risk  for  developing  a  HAMA  re-
sponse  has  been  reported  with  Bexxar
therapy (and the risk appears to be higher
without prior chemo- or immunotherapy).
HAMA can result in falsely elevated bio-
markers, but does not cause an increased risk
for infusion reactions. In most of cases, the
HAMA titers resolve spontaneously. How-
ever, the presence of HAMA may alter the
bio-distribution and is a contraindication to
future immunotherapy [34]. Follow up imag-
ing after RIT can be performed as per the rec-
ommended guidelines [39]. RIT with Zevalin
and Bexxar does not preclude further treat-
ment with other modalities [40,41].
ONGOING CONCERNS AND FUTURE
DIRECTIONS IN RIT
Radionuclide of choice for lymphoma
Different properties such as mean en-
ergy, effective path length, clearance, and
slightly differing toxicity profile may affect
the choice of radio-immunotherapeutic agent.
However, there is currently no clear clinical
consensus as to which agent would be supe-
rior in a specific clinical scenario, and there
are no direct randomized clinical trials com-
paring efficacy of Zevalin and Bexxar [42].
The reported studies significantly differ in pa-
tient selection, prior and concurrent treat-
ments, treatment length, response evaluation,
follow-up criteria, etc., and it is difficult to
draw an accurate comparison. Zevalin may
be  effective  for  bulkier  tumors  given  its
higher energy and relatively larger effective
path length. The reported risk of antibody re-
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nancies are relatively less for Zevalin. Over-
all, the Bexxar labeling process is easier;
however, the administration requires individ-
ualized dosimetric calculations and appropri-
ate  radiation  safety  precautions  for  the
concomitant gamma emission. Hematologi-
cal toxicity has been reported to be less se-
vere for Bexxar therapy, and it may be the
preferred agent in patients with more limited
marrow reserve. Though both Zevalin and
Bexxar target the B-cell CD-20+ antigen,
there is a subtle difference in the predominant
binding to the amino versus carboxy terminal
of the motif respectively [43,44]. Though this
theoretically results in slightly different func-
tional activity and therapeutic mechanisms,
the clinical significance of this is uncertain.
For all practical purposes, based on the cur-
rent knowledge, both Zevalin and Bexxar
share similar clinical utility with comparable
ORR and CR rates.
Dosimetry scans 
There is consensus on utilizing a dosi-
metric approach for Bexxar therapy with an
individualized  dose  determination  based
upon the variation in patient clearance rates
in an attempt to increase the therapeutic ef-
fectiveness of the therapy, while minimizing
possible toxicity.
In Europe, the 111In-Zevalin administra-
tion and scanning prior to Zevalin therapy
administration may be omitted. However, a
previous study reports possibility of altered
distribution and the need for the initial bio-
distribution scan [45]. 
Expanded role 
There is a concern in the lymphoma com-
munity regarding underutilization of RIT, de-
spite FDA approval for specific indications.
The utility of these agents has been recog-
nized, but their use is not widespread due to
various barriers with only a very small popu-
lation of eligible patients receiving the RIT
treatment [46]. Some of these barriers include
regulatory  and  reimbursement  challenges,
complex  referral  and  coordination  efforts,
self-referral office based practices for non-ra-
dioactive alternate therapies, and a perception
of increased health care costs. These obstacles
necessitate appropriate changes to streamline
the RIT process and provide evidence based
cost-effective health care to patients [47]. The
current ongoing research and recent clinical
trials are likely to expand the utility of RIT as
a concomitant and/or first-line therapeutic
agent for lymphoma treatment [48]. The pre-
dominant and dose limiting adverse effect for
RIT is hematological toxicity. Therefore, RIT
therapy in cases with more than 25 percent
marrow involvement is contraindicated at the
current time. However, newer protocols such
as fractionation and concomitant stem cell
transplant (SCT) with decreased hematologi-
cal toxicity and improved dose delivery might
lead to a change in these indications and con-
traindications. 
Dosing Strategies
Dose  intensification  can  be  achieved
through different methods and protocols [49]. A
higher myeloablative dose can be given along
with stem cell transplant, thereby potentially
achieving higher remission rates [50,51]. The
toxicity in such an approach is higher compared
to  the  current  approved  non-ablative  treat-
ments; however, it would still be better than the
conventional chemotherapy. Fractionated strat-
egy involves use of multiple fractions of the ra-
diation  dose  in  comparison  to  the  current
approved  single  dose  [52,53].  It  has  been
demonstrated in radiation oncology that frac-
tionated radiation treatments result in higher,
uniform dose delivery and lesser toxicity. The
exact role of this strategy in RIT is not yet de-
fined, but in concept could result in more ef-
fective  treatment.  Pre-targeting  involves
separation of the therapeutic radionuclide de-
livery process (90Y-DOTA-biotin) subsequent
to a separate delivery of the target molecule
(anti-CD20+ mAbs, conjugated to streptavidin)
and can be performed as a two- or three-step
process. This approach provides higher tumor
to background ratios, dose escalation, and bet-
ter outcomes [54,55].
Subsequent therapy in cases of failed
RIT
Subsequent to a failed RIT, other thera-
pies (chemotherapy, immunotherapy, stem
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are not contraindicated. The side effects of
additional conventional therapy are not sig-
nificantly different in the post-RIT group
compared to a similar cohort without RIT
[35,40,41]. There are no studies that support
repeat RIT administration, although this is
feasible. Patients who develop a HAMA re-
sponse after RIT (with elevated titers) are
not candidates for future immunotherapy
and radio-immunotherapy due to the poten-
tial for altered bio-distribution of the agents. 
Radionuclides, antigens, antibodies and
carriers
Though most of these radionuclide agents
are still investigational and not FDA approved,
several beta, alpha [56,57], and low energy
electron  [58,59]  emitting  radionuclides  are
being investigated and demonstrate a promis-
ing role for RIT. Each class of the above agents
offers distinct advantages for RIT due to their
physical decay and pharmacokinetic character-
istics [60], and these are detailed in Table 1.
These agents have been used with variable clin-
ical success in the clinical trials for various tu-
mors [61]. There is also growing interest in the
application of this technology for certain re-
sistant infections such as fungal or HIV, which
are not easily cured by conventional treatments
[62].
Several phase I and phase II studies are
being conducted with beta-emitting radionu-
clides labeled with anti CEA mAbs for col-
orectal cancer, anti PMSA mAbs targeting the
external domain for prostate cancer, intraperi-
toneal administration of MUC1 antibody for
ovarian cancer, and antitenascin antibodies for
brain tumors [56-61]. RIT with beta and alpha
emitters  appears  promising  for  adjunctive
treatment of hematological malignancies such
as acute leukemia. Unlike hematological ma-
lignancies, application of RIT to solid tumors
has been limited for several reasons such as
lesser radiosensitivity, low tumor vascularity,
and lower dose accretion resulting in failure to
deliver an adequate and effective tolerable ra-
diation dose. However, newer dosing strate-
gies and protocols detailed in the above section
provide dose escalation and intensification that
may overcome some of the inherent limitations
in  administration  of  RIT  to  solid  tumors
[56,63,64]. Pre-clinical studies have shown
that alpha-targeted RIT might be of benefit in
low tumor burden or micro-metastatic disease
due to the high LET and RBE associated with
alpha particles. Alpha particle therapy is also
being  investigated  for  conditions  such  as
leukemias, lymphomas, gliomas, melanoma,
and peritoneal carcinomatosis. The Auger elec-
trons are low-energy electrons that should be
deposited only in the immediate nuclear vicin-
ity and have potential for adjunctive treatments
[65]. A recent study reported utility of Auger
electrons from 125I labeled 35A7, an anti-CEA
antibody for small volume peritoneal carcino-
matosis after cytoreductive surgery, as opposed
to chemotherapy, which has rather non-uni-
form dose distribution [66]. Recently, 111In-
NLS-7G3,  an  auger  electron-emitting
radionuclide targeting CD-123 was reported to
be promising for leukemia in animal studies
[59].
There is an ongoing search for newer
antigens representing ideal antibody targets.
For example, a recent study reported use of
90Y-epratuzumab tetraxetan (a radiolabeled
mAb to CD-22 antigen) in NHLpatients with
a higher dose delivery and better objective re-
sponse [53,67]. A smaller radionuclide carrier
results in more uniform distribution and better
clearance with an opportunity for dose esca-
lation. The ultimate role of humanized anti-
bodies, fragments, diabodies, minibodies in
comparison to the conventional murine mAbs
is unclear. Newer antibody mimics such as
small molecular constructs and selective high
affinity ligands targeting HLA-DR10 recep-
tor may offer a novel approach for RIT in
hematological malignancies [68,69]. RIT may
find a role in early and concomitant/cocktail
treatment of lymphoma. 
CONCLUSIONS
There  have  been  significant  develop-
ments in RIT since Paul Ehrlich’s Seitenket-
Tentheorie of selective targeting with “magic
bullets” to the current day of “radioactive
magic bullets.” Although the current role of
RIT is primarily focused on lymphoma, future
advances will serve to expand its role with in-
404 Chamarthy et al.: Radioimmunotherapy of non-Hodgkin’s lymphomadividualized treatment options for multiple tu-
mors that will hopefully result in greater cure
rates with decreased systemic toxicity.
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